+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Benign Prostatic Hyperplasia Treatment Market - Global Forecast 2026-2032- Product Image
Benign Prostatic Hyperplasia Treatment Market - Global Forecast 2026-2032- Product Image
Sale

Benign Prostatic Hyperplasia Treatment Market - Global Forecast 2026-2032

  • Report

  • 187 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 4989822
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Benign Prostatic Hyperplasia Treatment Market is projected to reach USD 9.74 Billion in 2026. It is expected to continue growing at a CAGR of 6.12%, reaching USD 13.96 Billion by 2032.

Benign prostatic hyperplasia (BPH) treatment is evolving from broad symptom control toward personalized, risk-stratified management of lower urinary tract symptoms in aging men. BPH prevalence rises sharply with age, and clinical guidance from the American Urological Association (AUA), European Association of Urology (EAU), and NICE supports a stepped pathway that includes watchful waiting, lifestyle modification, alpha blockers, 5-alpha-reductase inhibitors, combination therapy, minimally invasive surgical therapies, and definitive procedures.

Market momentum is supported by global demographic aging, higher diagnosis rates, tele-urology adoption, and patient preference for therapies that preserve sexual function and reduce catheterization, hospitalization, and recovery time. Competitive differentiation increasingly depends on clinical durability, safety, reimbursement access, physician training, and real-world evidence demonstrating outcomes across prostate size, anatomy, comorbidity, and medication history.

Transformative Shifts in the BPH Treatment Landscape

The BPH treatment landscape is shifting as minimally invasive surgical therapies, including prostatic urethral lift, water vapor thermal therapy, temporary implanted prostatic devices, aquablation, and embolization approaches, expand options between long-term medication and traditional surgery. These therapies address demand for faster recovery and lower sexual side-effect burden, while transurethral resection of the prostate, laser enucleation, and other definitive interventions remain important for larger glands, urinary retention, and severe obstruction.

Pharmaceutical strategies are also changing. Alpha blockers remain widely used for rapid symptom relief, while 5-alpha-reductase inhibitors are prioritized for enlarged prostates and disease progression risk. Combination therapy, medication adherence support, and shared decision-making are increasingly central as clinicians balance symptom improvement, adverse effects, cost, and long-term retreatment risk.

Cumulative Impact of Artificial Intelligence on BPH Care

Artificial intelligence is beginning to influence BPH care through imaging interpretation, symptom scoring, workflow automation, clinical decision support, and predictive analytics. AI-enabled tools can help urologists evaluate prostate volume, bladder outlet obstruction risk, medication response probability, and post-procedure complications when integrated with validated clinical data and physician oversight.

The cumulative impact is most visible in care pathway efficiency. Digital intake, remote monitoring, natural-language processing of clinical notes, and AI-assisted triage can reduce delays from symptom onset to specialist evaluation. However, adoption depends on transparent algorithms, bias monitoring, cybersecurity, regulatory compliance, and validation across diverse populations because BPH outcomes vary by age, anatomy, comorbidities, and access to urologic care.

Key Regional Insights: BPH Treatment Demand by Geography

Asia-Pacific is a high-growth region for BPH treatment due to rapid aging in China, Japan, South Korea, and Australia, combined with expanding specialist capacity in India and ASEAN markets. Japan is among the world’s oldest societies, and China and South Korea are experiencing sustained growth in older male populations, strengthening demand for diagnostic evaluation, chronic medication, and minimally invasive treatment. North America remains a major innovation and reimbursement hub, supported by high urology procedure volumes, Medicare-aged demand in the United States, strong adoption of minimally invasive technologies, and established guideline-based care.

Europe benefits from structured health technology assessment, broad clinical guideline alignment, and mature urology service networks, particularly across the European Union and the United Kingdom. Latin America shows rising demand as Brazil and Mexico expand private healthcare access and urban specialty care capacity, although affordability and uneven access continue to affect treatment uptake. The Middle East, led by GCC investment in specialty hospitals and tertiary care, is increasing access to advanced urologic procedures. Africa remains more uneven, with BPH treatment access linked to urban hospital investment, workforce development, diagnostic availability, and improved access to essential urology services.

Key Group Insights Across ASEAN, GCC, EU, BRICS, G7, and NATO

ASEAN markets are characterized by rising diagnosis, medical tourism corridors, and expanding private hospital networks, creating opportunities for cost-effective medications and scalable minimally invasive BPH procedures. GCC countries are investing in tertiary care, robotic surgery infrastructure, and international clinical partnerships, supporting adoption of advanced urology platforms among high-income patient populations and expatriate communities.

The European Union emphasizes evidence, safety, procurement value, and reimbursement discipline, favoring BPH treatment products supported by comparative outcomes and durable data. BRICS countries represent substantial long-term clinical need due to large aging male populations, but access, pricing, hospital infrastructure, and reimbursement vary widely across member economies. G7 markets generally lead in technology adoption, clinical trial activity, and guideline implementation, while NATO-aligned systems outside the G7 often follow European and North American standards for training, quality, device regulation, and health system readiness.

Key Country Insights: Priority BPH Treatment Markets

The United States is a leading environment for BPH treatment innovation, supported by specialty urology networks, Medicare-aged demand, and availability of minimally invasive and surgical options. Canada shows steady demand through publicly funded pathways and private adjunct services, while Mexico and Brazil combine expanding middle-class healthcare access with large populations that remain underdiagnosed or undertreated. In Europe, the United Kingdom, Germany, France, Italy, and Spain emphasize guideline-based care, reimbursement evidence, clinical efficiency, and procedure quality; Russia maintains demand from an aging male population but faces access, affordability, and supply-chain variability.

China and India represent major long-term opportunities because of aging demographics, improving diagnostic penetration, and expanding hospital capacity, although affordability and hospital tier differences shape uptake. Japan and South Korea support advanced procedural adoption due to aging populations, sophisticated health systems, and high expectations for functional outcomes. Australia shows strong alignment with evidence-based urology practice and private-sector access to newer procedures, reinforcing demand for therapies that reduce recovery time and preserve quality of life.

Actionable Recommendations for BPH Treatment Industry Leaders

Industry leaders should prioritize differentiated clinical evidence that compares symptom improvement, urinary flow, retreatment rates, sexual function preservation, adverse events, catheter dependence, and recovery time across therapies. Evidence packages should be designed for urologists, payers, procurement committees, and patients, with real-world registries strengthening claims beyond pivotal trials.

Commercial execution should combine physician education, patient decision aids, reimbursement strategy, and service-line partnerships with high-volume urology centers. Organizations should localize pricing, training, and distribution models for emerging markets while maintaining regulatory quality. Digital symptom tracking, AI-assisted care navigation, and post-procedure monitoring can improve adherence, patient satisfaction, and longitudinal outcome measurement.

Research Methodology

This executive summary is grounded in secondary research from recognized clinical and public health sources, including urology guidelines, peer-reviewed literature, regulatory updates, hospital practice trends, demographic data, and reimbursement frameworks. Evidence was assessed for clinical relevance to BPH treatment pathways, including pharmacologic therapy, minimally invasive interventions, and surgical management.

The methodology emphasizes triangulation across guideline recommendations, epidemiology, technology adoption signals, and regional healthcare access indicators. Insights were structured to support strategic planning, market prioritization, executive communication, and decision-making for stakeholders across medical devices, pharmaceuticals, digital health, provider organizations, and healthcare investors.

Conclusion

BPH treatment is moving toward more personalized, less invasive, and data-enabled care. Aging populations, rising patient expectations, and expanding procedure portfolios are increasing demand for solutions that improve urinary symptoms while limiting recovery time and preserving quality of life.

The strongest opportunities will favor organizations that combine durable clinical outcomes, physician training, patient-centered education, payer-ready evidence, and responsible digital innovation. As AI, minimally invasive therapies, and regional healthcare investment converge, the BPH treatment landscape is positioned for sustained transformation across developed and emerging health systems.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Benign Prostatic Hyperplasia Treatment Market, by Treatment Type
7.1. Introduction
7.2. Medications
7.2.1. 5-Alpha-Reductase Inhibitors
7.2.2. Alpha Blockers
7.3. Minimally Invasive Therapies
7.3.1. Prostate Artery Embolization
7.3.2. Water Vapour Therapy
7.4. Surgical Treatments
7.4.1. Laser Surgery
7.4.2. Prostatic Urethral Lift
7.4.3. Transurethral Incision Of The Prostate
7.4.4. Transurethral Resection Of The Prostate
8. Benign Prostatic Hyperplasia Treatment Market, by Product Type
8.1. Introduction
8.2. Catheters
8.3. Electrodes
8.4. Implants
8.5. Prostatic Stents
8.6. Resectoscopes
8.7. Urology Laser
9. Benign Prostatic Hyperplasia Treatment Market, by End User
9.1. Introduction
9.2. Ambulatory Surgical Centers
9.3. Clinics
9.4. Homecare
9.5. Hospitals
10. Benign Prostatic Hyperplasia Treatment Market, by Distribution Channel
10.1. Introduction
10.2. Offline
10.3. Online
11. Benign Prostatic Hyperplasia Treatment Market, by Region
11.1. Asia-Pacific
11.2. North America
11.3. Latin America
11.4. Europe
11.5. Middle East
11.6. Africa
12. Benign Prostatic Hyperplasia Treatment Market, by Group
12.1. ASEAN
12.2. GCC
12.3. European Union
12.4. BRICS
12.5. G7
12.6. NATO
13. Benign Prostatic Hyperplasia Treatment Market, by Country
13.1. United States
13.2. Germany
13.3. China
13.4. United Kingdom
13.5. India
13.6. Japan
13.7. Russia
13.8. Brazil
13.9. Canada
13.10. Italy
13.11. Mexico
13.12. France
13.13. Spain
13.14. Australia
13.15. South Korea
14. Competitive Landscape
14.1. Market Share Analysis, 2025
14.2. FPNV Positioning Matrix, 2025
14.3. Market Concentration Analysis, 2025
14.3.1. Concentration Ratio (CR)
14.3.2. Herfindahl Hirschman Index (HHI)
14.4. Recent Developments & Impact Analysis, 2025
14.5. Product Portfolio Analysis, 2025
14.6. Benchmarking Analysis, 2025
15. Company Profiles
15.1. AbbVie Inc.
15.2. Alembic Pharmaceuticals Limited
15.3. Asahi Kasei Corporation
15.4. Astellas Pharma Inc.
15.5. Bayer AG
15.6. Boehringer Ingelheim GmbH
15.7. Boston Scientific Corporation
15.8. Cipla Ltd.
15.9. Coloplast Group
15.10. Dr. Reddy’s Laboratories
15.11. Eli Lilly and Company
15.12. Endo International PLC
15.13. GlaxoSmithKline plc
15.14. Hikma Pharmaceuticals PLC
15.15. IPG Photonics Corporation
15.16. Lumenis Ltd.
15.17. Olympus Corporation
15.18. Organon group of companies
15.19. PROCEPT BioRobotics Corporation
15.20. ProstaLund AB
15.21. Quanta System
15.22. Richard Wolf GmbH
15.23. Teleflex Incorporated
15.24. Urologix, LLC.
List of Figures
FIGURE 1. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
FIGURE 9. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 11. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 13. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 15. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 17. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 19. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 21. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL MEDICATIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL MEDICATIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL MEDICATIONS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL 5-ALPHA-REDUCTASE INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL 5-ALPHA-REDUCTASE INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL 5-ALPHA-REDUCTASE INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL ALPHA BLOCKERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL ALPHA BLOCKERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL ALPHA BLOCKERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL MINIMALLY INVASIVE THERAPIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL MINIMALLY INVASIVE THERAPIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL MINIMALLY INVASIVE THERAPIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL PROSTATE ARTERY EMBOLIZATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL PROSTATE ARTERY EMBOLIZATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL PROSTATE ARTERY EMBOLIZATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL WATER VAPOUR THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL WATER VAPOUR THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL WATER VAPOUR THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL SURGICAL TREATMENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL SURGICAL TREATMENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL SURGICAL TREATMENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL LASER SURGERY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL LASER SURGERY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL LASER SURGERY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL PROSTATIC URETHRAL LIFT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL PROSTATIC URETHRAL LIFT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL PROSTATIC URETHRAL LIFT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL TRANSURETHRAL INCISION OF THE PROSTATE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL TRANSURETHRAL INCISION OF THE PROSTATE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL TRANSURETHRAL INCISION OF THE PROSTATE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL TRANSURETHRAL RESECTION OF THE PROSTATE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL TRANSURETHRAL RESECTION OF THE PROSTATE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL TRANSURETHRAL RESECTION OF THE PROSTATE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL CATHETERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL CATHETERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL CATHETERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL ELECTRODES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL ELECTRODES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL ELECTRODES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL IMPLANTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL IMPLANTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL IMPLANTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL PROSTATIC STENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL PROSTATIC STENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL PROSTATIC STENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL RESECTOSCOPES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL RESECTOSCOPES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL RESECTOSCOPES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL UROLOGY LASER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL UROLOGY LASER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL UROLOGY LASER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL HOMECARE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL HOMECARE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL HOMECARE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL OFFLINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL OFFLINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL OFFLINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL ONLINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL ONLINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL ONLINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 77. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 78. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 79. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2017-2032 (USD MILLION)
TABLE 80. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2017-2032 (USD MILLION)
TABLE 81. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2017-2032 (USD MILLION)
TABLE 82. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 83. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 84. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 85. NORTH AMERICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 86. NORTH AMERICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 87. NORTH AMERICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2017-2032 (USD MILLION)
TABLE 88. NORTH AMERICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2017-2032 (USD MILLION)
TABLE 89. NORTH AMERICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2017-2032 (USD MILLION)
TABLE 90. NORTH AMERICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 91. NORTH AMERICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 92. NORTH AMERICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 93. LATIN AMERICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 94. LATIN AMERICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 95. LATIN AMERICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2017-2032 (USD MILLION)
TABLE 96. LATIN AMERICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2017-2032 (USD MILLION)
TABLE 97. LATIN AMERICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2017-2032 (USD MILLION)
TABLE 98. LATIN AMERICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 99. LATIN AMERICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 100. LATIN AMERICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 101. EUROPE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 102. EUROPE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 103. EUROPE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2017-2032 (USD MILLION)
TABLE 104. EUROPE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2017-2032 (USD MILLION)
TABLE 105. EUROPE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2017-2032 (USD MILLION)
TABLE 106. EUROPE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 107. EUROPE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 108. EUROPE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 109. MIDDLE EAST BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 110. MIDDLE EAST BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 111. MIDDLE EAST BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2017-2032 (USD MILLION)
TABLE 112. MIDDLE EAST BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2017-2032 (USD MILLION)
TABLE 113. MIDDLE EAST BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2017-2032 (USD MILLION)
TABLE 114. MIDDLE EAST BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 115. MIDDLE EAST BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 116. MIDDLE EAST BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 117. AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 118. AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 119. AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2017-2032 (USD MILLION)
TABLE 120. AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2017-2032 (USD MILLION)
TABLE 121. AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2017-2032 (USD MILLION)
TABLE 122. AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 123. AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 124. AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 125. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 126. ASEAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 127. ASEAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 128. ASEAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2017-2032 (USD MILLION)
TABLE 129. ASEAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2017-2032 (USD MILLION)
TABLE 130. ASEAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2017-2032 (USD MILLION)
TABLE 131. ASEAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 132. ASEAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 133. ASEAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 134. GCC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 135. GCC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 136. GCC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2017-2032 (USD MILLION)
TABLE 137. GCC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2017-2032 (USD MILLION)
TABLE 138. GCC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2017-2032 (USD MILLION)
TABLE 139. GCC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 140. GCC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 141. GCC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 142. EUROPEAN UNION BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 143. EUROPEAN UNION BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 144. EUROPEAN UNION BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2017-2032 (USD MILLION)
TABLE 145. EUROPEAN UNION BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2017-2032 (USD MILLION)
TABLE 146. EUROPEAN UNION BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2017-2032 (USD MILLION)
TABLE 147. EUROPEAN UNION BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 148. EUROPEAN UNION BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 149. EUROPEAN UNION BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 150. BRICS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 151. BRICS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 152. BRICS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2017-2032 (USD MILLION)
TABLE 153. BRICS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2017-2032 (USD MILLION)
TABLE 154. BRICS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2017-2032 (USD MILLION)
TABLE 155. BRICS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 156. BRICS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 157. BRICS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 158. G7 BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 159. G7 BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 160. G7 BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2017-2032 (USD MILLION)
TABLE 161. G7 BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2017-2032 (USD MILLION)
TABLE 162. G7 BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2017-2032 (USD MILLION)
TABLE 163. G7 BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 164. G7 BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 165. G7 BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 166. NATO BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 167. NATO BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 168. NATO BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2017-2032 (USD MILLION)
TABLE 169. NATO BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2017-2032 (USD MILLION)
TABLE 170. NATO BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2017-2032 (USD MILLION)
TABLE 171. NATO BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 172. NATO BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 173. NATO BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 174. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 175. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 176. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 177. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2017-2032 (USD MILLION)
TABLE 178. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2017-2032 (USD MILLION)
TABLE 179. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2017-2032 (USD MILLION)
TABLE 180. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 181. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 182. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 183. GERMANY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 184. GERMANY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 185. GERMANY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2017-2032 (USD MILLION)
TABLE 186. GERMANY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2017-2032 (USD MILLION)
TABLE 187. GERMANY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2017-2032 (USD MILLION)
TABLE 188. GERMANY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 189. GERMANY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 190. GERMANY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 191. CHINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 192. CHINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 193. CHINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2017-2032 (USD MILLION)
TABLE 194. CHINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2017-2032 (USD MILLION)
TABLE 195. CHINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2017-2032 (USD MILLION)
TABLE 196. CHINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 197. CHINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 198. CHINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 199. UNITED KINGDOM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 200. UNITED KINGDOM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 201. UNITED KINGDOM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2017-2032 (USD MILLION)
TABLE 202. UNITED KINGDOM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2017-2032 (USD MILLION)
TABLE 203. UNITED KINGDOM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2017-2032 (USD MILLION)
TABLE 204. UNITED KINGDOM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 205. UNITED KINGDOM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 206. UNITED KINGDOM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 207. INDIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 208. INDIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 209. INDIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2017-2032 (USD MILLION)
TABLE 210. INDIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2017-2032 (USD MILLION)
TABLE 211. INDIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2017-2032 (USD MILLION)
TABLE 212. INDIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 213. INDIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 214. INDIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 215. JAPAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 216. JAPAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 217. JAPAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2017-2032 (USD MILLION)
TABLE 218. JAPAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2017-2032 (USD MILLION)
TABLE 219. JAPAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2017-2032 (USD MILLION)
TABLE 220. JAPAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 221. JAPAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 222. JAPAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 223. RUSSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 224. RUSSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 225. RUSSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2017-2032 (USD MILLION)
TABLE 226. RUSSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2017-2032 (USD MILLION)
TABLE 227. RUSSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2017-2032 (USD MILLION)
TABLE 228. RUSSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 229. RUSSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 230. RUSSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 231. BRAZIL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 232. BRAZIL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 233. BRAZIL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2017-2032 (USD MILLION)
TABLE 234. BRAZIL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2017-2032 (USD MILLION)
TABLE 235. BRAZIL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2017-2032 (USD MILLION)
TABLE 236. BRAZIL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 237. BRAZIL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 238. BRAZIL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 239. CANADA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 240. CANADA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 241. CANADA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2017-2032 (USD MILLION)
TABLE 242. CANADA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2017-2032 (USD MILLION)
TABLE 243. CANADA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2017-2032 (USD MILLION)
TABLE 244. CANADA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 245. CANADA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 246. CANADA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 247. ITALY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 248. ITALY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 249. ITALY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2017-2032 (USD MILLION)
TABLE 250. ITALY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2017-2032 (USD MILLION)
TABLE 251. ITALY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2017-2032 (USD MILLION)
TABLE 252. ITALY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 253. ITALY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 254. ITALY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 255. MEXICO BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 256. MEXICO BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 257. MEXICO BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2017-2032 (USD MILLION)
TABLE 258. MEXICO BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2017-2032 (USD MILLION)
TABLE 259. MEXICO BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2017-2032 (USD MILLION)
TABLE 260. MEXICO BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 261. MEXICO BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 262. MEXICO BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 263. FRANCE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 264. FRANCE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 265. FRANCE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2017-2032 (USD MILLION)
TABLE 266. FRANCE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2017-2032 (USD MILLION)
TABLE 267. FRANCE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2017-2032 (USD MILLION)
TABLE 268. FRANCE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 269. FRANCE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 270. FRANCE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 271. SPAIN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 272. SPAIN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 273. SPAIN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2017-2032 (USD MILLION)
TABLE 274. SPAIN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2017-2032 (USD MILLION)
TABLE 275. SPAIN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2017-2032 (USD MILLION)
TABLE 276. SPAIN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 277. SPAIN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 278. SPAIN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 279. AUSTRALIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 280. AUSTRALIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 281. AUSTRALIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2017-2032 (USD MILLION)
TABLE 282. AUSTRALIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2017-2032 (USD MILLION)
TABLE 283. AUSTRALIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2017-2032 (USD MILLION)
TABLE 284. AUSTRALIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 285. AUSTRALIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 286. AUSTRALIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 287. SOUTH KOREA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 288. SOUTH KOREA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 289. SOUTH KOREA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2017-2032 (USD MILLION)
TABLE 290. SOUTH KOREA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2017-2032 (USD MILLION)
TABLE 291. SOUTH KOREA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2017-2032 (USD MILLION)
TABLE 292. SOUTH KOREA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 293. SOUTH KOREA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 294. SOUTH KOREA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 295. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
TABLE 296. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

Companies Mentioned

  • AbbVie Inc.
  • Alembic Pharmaceuticals Limited
  • Asahi Kasei Corporation
  • Astellas Pharma Inc.
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Boston Scientific Corporation
  • Cipla Ltd.
  • Coloplast Group
  • Dr. Reddy’s Laboratories
  • Eli Lilly and Company
  • Endo International PLC
  • GlaxoSmithKline plc
  • Hikma Pharmaceuticals PLC
  • IPG Photonics Corporation
  • Lumenis Ltd.
  • Olympus Corporation
  • Organon group of companies
  • PROCEPT BioRobotics Corporation
  • ProstaLund AB
  • Quanta System
  • Richard Wolf GmbH
  • Teleflex Incorporated
  • Urologix, LLC.

Table Information

Report AttributeDetails
No. of Pages187
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 9.74 Billion
Forecasted Market Value ( USD ) by 2032 $ 13.96 Billion
Compound Annual Growth Rate6.1%
Regions CoveredGlobal
No. of Companies Mentioned24

Related Topics

Related Reports

Benign Prostatic Hyperplasia Treatment Market Size, Share, Trends and Forecast by Treatment Type, and Region, 2026-2034 - Product Image

Benign Prostatic Hyperplasia Treatment Market Size, Share, Trends and Forecast by Treatment Type, and Region, 2026-2034

  • Report
  • 145 Pages
  • Global
From
Benign Prostatic Hyperplasia Treatment Market Report 2026 - Product Image

Benign Prostatic Hyperplasia Treatment Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Benign Prostatic Hyperplasia (Bph) Treatment Devices and Equipment Market Outlook 2025-2034: Market Share, and Growth Analysis - Product Image

Benign Prostatic Hyperplasia (Bph) Treatment Devices and Equipment Market Outlook 2025-2034: Market Share, and Growth Analysis

  • Report
  • 160 Pages
  • Global
From
Benign Prostatic Hyperplasia Surgical Treatment Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Benign Prostatic Hyperplasia Surgical Treatment Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Benign Prostatic Hyperplasia (BPH) Drugs - Global Strategic Business Report - Product Image

Benign Prostatic Hyperplasia (BPH) Drugs - Global Strategic Business Report

  • Report
  • 210 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.